| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Aethlon Medical, Inc.$1.96
+0.03 (+1.3%)
F 10Pipeline Score MedTech · Pre-Clinical
Market Cap
3.47 M
EPS
-45.83
P/E Ratio
-0.05 $
Value Trade
573.39 K
SEC Financials
Q4 2025Dilution Risk
R&D Expenses
532.78 K
Total Assets
8.06 M
Total Liabilities
1.34 M
Equity
6.71 M
D/E Ratio
12,345
2.8 %
Week
-3.93 %
1 Month
7.84 %
3 Month
-38.55 %
6 Month
-99.84 %
5 Year
-100 %
All Time
Cash Data
Cash Position
6.96 M
Monthly Burn
687.00 K
Runway
6.2 mo
Burn Trend
SEC Filing
Feb 12, 2026
Overview
Volume
41.35 K
52 Week Range
1.36 - 29.88
% held by Insiders
4.11 %
% held by Institutions
6.46 %
Enterprise Value
-3.07 M
Total Shares
1.31 M
Short %
14.55 %
Float Shares
1.31 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F10
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 9%
Micro Cap (rank 825 of 905)
Percentile RankAethlon Medical, Inc. has significant pipeline risk (10/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Hemopurifier® | cancer,Long COVID | Phase 1 | 2025-06-26 | |||
Hemopurifier® | cancer,Long COVID | Phase 1 | 2025-06-26 | |||
Hemopurifier® | cancer,Long COVID | Phase 1 | 2025-06-26 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AEMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
AEMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AEMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AEMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AEMD Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
AEMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AEMDAethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
Aethlon Medical reported its fiscal year-end results for March 31, 2026, highlighting advancements in its Australian oncology study, which has now entered its third dosing cohort. The company also expanded its Hemopurifier intellectual property portfolio and achieved a significant reduction in operating expenses. Despite these advancements, Aethlon continues to face substantial net losses and limited cash reserves.
Read more →AEMDAethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026
Aethlon Medical, Inc. will announce its fiscal year-end financial results on June 10, 2026, followed by a conference call to discuss the results and recent developments. The Hemopurifier, a key product in their pipeline, has shown promise in clinical studies for treating cancer and life-threatening viral infections. Interested parties can register for the call or access a replay afterward.
Read more →AEMDAethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness
Aethlon Medical is monitoring the Bundibugyo Ebola virus outbreak in the Democratic Republic of the Congo and Uganda, reaffirming its preparedness to engage with healthcare authorities regarding its Hemopurifier technology. The device has shown potential in past cases, although it remains investigational for Ebola treatment. The company emphasizes the need for broad-spectrum therapies in the face of limited approved treatments.
Read more →AEMDAethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review
Aethlon Medical, Inc. has received a positive recommendation from the Data Safety Monitoring Board (DSMB) to advance to the final cohort of its clinical trial for the Hemopurifier device. The DSMB noted no safety concerns during their review of the second cohort, allowing the trial to proceed with further evaluations of safety and dosing. Enrollment for the final cohort is now open, with participants receiving three treatments over a week.
Read more →AEMDAethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities
Aethlon Medical has engaged Maxim Group LLC as its exclusive financial advisor to explore strategic opportunities, including potential partnerships and acquisitions. The company is also progressing with its oncology trial in Australia, having completed the second cohort. However, there is no set timeline for the evaluation process, and no guarantees exist regarding the outcome of these discussions.
Read more →AEMDAethlon Medical to Present on the Emerging Growth Conference on February 25th 2026
Aethlon Medical, Inc. will present at the Emerging Growth Conference on February 25, 2026. The event will feature a live interactive session with the CEO and CFO, allowing attendees to engage directly. The Hemopurifier, an investigational device for treating cancer and infectious diseases, holds a Breakthrough Device Designation from the FDA.
Read more →AEMDAethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update
Aethlon Medical reported its fiscal Q3 2026 financial results, highlighting ongoing clinical trials and cost efficiencies. The company is advancing its Hemopurifier technology, showing promise in cancer treatment and Long COVID research. Despite an increase in operating loss, Aethlon's commitment to clinical programs remains strong, with a focus on optimizing costs.
Read more →AEMDAethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026
Aethlon Medical, Inc. will announce its fiscal third quarter financial results on February 12, 2026, at 4:15 p.m. ET. Following the release, management will host a conference call at 4:30 p.m. ET to discuss the results and recent developments. The Hemopurifier device, aimed at treating cancer and viral infections, has received FDA Breakthrough Device designation.
Read more →AEMDAethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million
Aethlon Medical, Inc. has announced a private placement agreement with an institutional investor, aiming to raise approximately $3.3 million. The deal includes the sale of shares and warrants priced at $4.03 each. The offering is expected to close by December 8, 2025, pending customary conditions. The company plans to use the funds to further develop its Hemopurifier technology.
Read more →AEMDAethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs
Aethlon Medical has published preclinical data indicating that its Hemopurifier can bind to extracellular vesicles in Long COVID patient samples, potentially decreasing inflammatory microRNAs. This study, conducted in collaboration with UCSF, suggests that the Hemopurifier may serve as a therapeutic option for Long COVID, which currently lacks effective treatments.
Read more →AEMDAethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update
Aethlon Medical, Inc. reported its fiscal Q2 2025 financial results, highlighting significant progress in clinical trials and a 48% reduction in operating expenses. The company is advancing its Hemopurifier device in oncology trials, with recruitment for a second cohort underway. Despite positive developments, challenges remain, including the limited effectiveness of current therapies for patients.
Read more →AEMDAethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025
Aethlon Medical, Inc. will release its fiscal second quarter financial results on November 12, 2025, at 4:15 p.m. ET. Following this, a conference call will be held at 4:30 p.m. ET to discuss the results and recent corporate developments. The Hemopurifier, an investigational device, aims to treat advanced cancer and life-threatening viral infections.
Read more →AEMDAethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial
Aethlon Medical has reported preliminary findings from its oncology clinical trial in Australia, focusing on the Hemopurifier device. Initial results from three patients indicate positive changes in extracellular vesicles, microRNAs, and lymphocyte counts after treatment. However, the company cautions that these observations do not imply clinical efficacy, as further data is needed from subsequent cohorts.
Read more →AEMDAethlon Medical Announces Pricing of $4.5 Million Public Offering
Aethlon Medical has announced a public offering of 5 million shares at $0.90 each, aiming to raise approximately $4.5 million. The proceeds will be used for general corporate purposes, including clinical trials and research. The offering is expected to close around September 5, 2025, pending customary conditions.
Read more →AEMDAethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC)
Aethlon Medical announced the issuance of two patents for its Hemopurifier device, aimed at treating Long COVID and COVID-19-associated coagulopathy. The U.S. Patent No. 12,409,260 will protect the use of the device for patients with Long COVID symptoms, while the Unitary European Patent 4136453 covers treatment for CAC. These patents enhance Aethlon's intellectual property in critical medical areas.
Read more →AEMDAethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update
Aethlon Medical reported financial results for Q1 2025, highlighting progress in its Australian oncology trial where the first treatment cohort was successfully completed. The company has reduced operating expenses by 32% and is advancing its Hemopurifier device, which aims to improve responses in patients unresponsive to PD-1 inhibitors. However, the initiation of a trial in India has been postponed to 2026, focusing resources on the Australian study.
Read more →AEMDAethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort
Aethlon Medical, Inc. announced that the Data Safety Monitoring Board has completed its safety review of the ongoing clinical trial AEMD-2022-06 and recommended advancing to the next patient cohort. The trial assesses the safety and feasibility of the Hemopurifier in patients with solid tumors. No serious adverse events have been reported, indicating a favorable safety profile.
Read more →Competitive Position
How AEMD ranks across every disease it competes inCompetitive Position is a premium feature
See how AEMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial